Investor Relations

Board of Directors & Scientific Board

Board of Directors & Scientific Board

Board of Directors

  • Robert Bitterman

    Robert Bitterman


    Mr. Bitterman has over 18 years of executive leadership experience in the pharmaceutical and biologic life science industry. He most recently served as the President and Chief Executive Officer of Cutanea Life Sciences, Inc., a private company he founded in 2005 that focused on developing innovative technologies to treat diseases and disorders of the skin and subcutaneous tissue, until its acquisition by Biofrontera, Inc., USA in March 2019. Prior to his role at Cutanea, Mr. Bitterman served as President and Chief Executive Officer of Isolagen, Inc., President and General Manager of Dermik Laboratories and various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University.

    Chairman of the Board
  • Geert Cauwenbergh, Dr. Med. Sc.

    Geert Cauwenbergh, Dr. Med. Sc.


    Dr. Cauwenbergh served as our President and Chief Executive Officer from April 2012 until his retirement in March 2019. Prior to joining Phio, Dr. Cauwenbergh served as Chairman and Chief Executive Officer of Barrier Therapeutics, Inc., a publicly-traded biopharmaceutical company he founded in 2001 that focused on dermatology drug development. Barrier was acquired by Stiefel Laboratories, Inc. in 2008. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years. He currently serves as a director of Moberg Pharma AB. Dr. Cauwenbergh received his Doctorate in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine (Belgium), where he also completed his masters and undergraduate work.

    • H. Paul Dorman

      H. Paul Dorman


      Mr. Dorman brings nearly three decades of executive experience in the pharmaceutical industry. He currently serves as the Chairman and CEO of DFB Pharmaceuticals, a holdings company specializing in investing in and operating pharmaceutical businesses. Prior to DFB, Mr. Dorman also was Chairman and CEO of DPT laboratories, a contract manufacturer and developer of pharmaceuticals products, and was employed by Johnson & Johnson for 12 years, where he served in various positions, including Vice President. Mr. Dorman holds a B.S. degree in Mechanical Engineering from Tulane University and a Juris Doctor of Law from Loyola University.

    • Robert Ferrara


      Mr. Ferrara most recently served as the Chief Financial Officer of Cutanea Life Sciences, Inc., a private company focused on developing innovative technologies to treat diseases and disorders of the skin and subcutaneous tissue. Prior to Cutanea, Mr. Ferrara served as the Chief Financial Officer of Storeroom Solutions Inc., a venture capital financed, technology enhanced, integrated supply chain solutions company and NER Data Products, Inc., an IT service management company, as well as holding other senior level financial positions in national and international public companies in the greater Philadelphia area. Mr. Ferrara previously served on the board of directors of the Planned Lifetime Assistance Network of Pennsylvania, where he was on the executive committee and chairman of the governance and audit committees. Mr. Ferrara received a B.S. in Accounting from Lehigh University and is a Certified Public Accountant.

    • Dr. Jonathan Freeman

      Dr. Jonathan Freeman


      Dr. Freeman currently serves as the Chief Operating Officer of Anthos Therapeutics Inc., a clinical-stage biopharmaceutical company developing therapies for cardiovascular patients. Anthos Therapeutics Inc. was launched by Novartis and Blackstone Life Sciences, a private investment firm, where Dr. Freeman has also served as a Senior Advisor since July 2018. Prior to Anthos, Dr. Freeman was the Chief Business Officer at Vedanta Biosciences and held the role of Senior Vice President of Strategy and Portfolio Management at Merck KGaA. During his tenure, he was responsible for the portfolio and strategic shift that repositioned Merck as a major player in the immuno-oncology space. Dr. Freeman received a Ph.D. in Molecular Pharmacology and Drug Metabolism from the Imperial Cancer Research Fund (now CRUK), an M.A. and First Class Honours in Biochemistry from Cambridge University and a MBA with a finance major from Webster, St. Louis.

    • Curtis Lockshin, Ph.D.

      Curtis Lockshin, Ph.D.


      Dr. Lockshin currently serves as the Chief Scientific Officer of Xenetic Biosciences, Inc., a biopharmaceutical company focused on the development of novel oncology therapeutics. Prior to Xenetic, Dr. Lockshin served as the Chief Technical Officer of VBI Vaccines, Inc., where he was the Chief Executive Officer of SciVac Therapeutics, Inc. until its acquisition by VBI in July 2016. Dr. Lockshin also held the role of Vice President of Corporate R&D Initiatives for OPKO Health, Inc., with operational responsibilities inside several of OPKO’s R&D units. He initially began his career as a scientist with Sepracor Inc. (now Sunovion Pharmaceuticals Inc.) and eventually became the research director responsible for the strategy and operations of Sepracor’s new leads initiative. Dr. Lockshin holds a S.B. degree in Life Sciences and a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology.

    Scientific Advisory Board

    • James D. Griffin, M.D.

      James D. Griffin, M.D.

      James D. Griffin, MD is the Chairman, Department of Medical Oncology at the Dana-Farber Cancer Institute; Professor, Medicine at Harvard Medical School and Director, Medical Oncology at Brigham and Women's Hospital. Dr. Griffin received his medical degree from Harvard Medical School in 1974. After residency training in internal medicine at Johns Hopkins Hospital, he completed a hematology fellowship at Massachusetts General Hospital and a medical oncology fellowship at Dana-Farber. In 1981, he joined the staff of Dana-Farber, where he is chair of the Department of Medical Oncology. From 1993 to 1998, Dr. Griffin was editor-in-chief of Blood. He is a professor of Medicine at Harvard Medical School and currently sits on the scientific advisory boards of the Lombardi Cancer Center at Georgetown University and the Johns Hopkins Cancer Center and Case Western Cancer Center.

      • Rolf Kiessling, M.D.

        Rolf Kiessling, M.D.

        Rolf Kiessling is a Professor in Experimental Oncology at the Karolinska Institutet and Senior Chief Physician of Radiumhemmet at Karolinska Hospital. Dr. Kiessling has broad scientific expertise in the field of experimental and clinical immunology and accredited with the discovery for Natural Killer cells (NK cells) during the mid-70’s. He has published more than 250 publications in peer-reviewed journals. Professor Kiessling has served as a Member of the Research Council at the Swedish Cancer Society and the Swedish Association for Medical Research.

        • Pamela Pavco, Ph.D.

          Pamela Pavco, Ph.D.

          Dr. Pavco has over 20 years of research and development experience in oligonucleotides. Dr. Pavco served as Phio's Chief Development Officer until May 2017. Prior to that, she joined Galena Biopharma, Inc. in March of 2007 and served served as the Senior Vice President of Pharmaceutical Development until April 2012. Dr. Pavco was Senior Director, Research and Development Project Management at Sirna Therapeutics, Inc., from 2002 until 2006, when it was acquired by Merck & Co., Inc. for $1.1 billion. While at Sirna, she was responsible for the discovery research and development of Sirna-027, the first chemically modified siRNA to enter clinical trials. Dr. Pavco also managed Sirna’s alliance with Allergan, Inc. that was initiated to continue discovery research in the area of ophthalmology and take Sirna-027 forward into Phase 2 clinical studies. While at Sirna, Dr. Pavco served in various additional capacities, including Director of Biology Research and Director of Pharmacology and she also managed numerous corporate collaborations and internal programs focusing on the development of therapeutic oligonucleotides in the fields of oncology, anti- angiogenesis, hepatitis, respiratory disease and Huntington’s disease. Dr. Pavco has authored numerous scientific articles and contributed to approximately 58 patents and patent applications in the oligonucleotide therapeutics field. Dr. Pavco received a Ph.D. in Biochemistry from Virginia Commonwealth University in 1983 and did her post-doctoral work at Duke University. She is a member of the American Association of Cancer Research and the Association for Research and Vision in Ophthalmology.